These results highlight glutamine metabolism, through its ability to support both mitochondrial function and cellular redox status, becomes a metabolic dependency of FLT3-mutant AML that can be combined with FLT3-inhibitor treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.